Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Sponsor: Atom Therapeutics Co., Ltd
Summary
This is a phase 2, international, multicenter, randomized, double blind, parallel group trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 28
Official title: A Phase 2, International, Multicenter, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2026-02-01
Completion Date
2028-01-31
Last Updated
2026-01-07
Healthy Volunteers
No
Conditions
Interventions
ABP-671 plus febuxostat Group 1
ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)
ABP-671 plus febuxostat Group 2
ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)
ABP-671 Group
ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)
Locations (8)
Genesis Research services
Newcastle, New South Wales, Australia
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China